Overview

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Status:
Completed
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
PF-06700841